TG THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
TG THERAPEUTICS, INC. (TGTX) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $13.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-05
- TG THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $13.09M, a 24.79% decline year-over-year.
- TG THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $14.56M, a 8.79% decline year-over-year.
- TG THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $18.13M, a 43.24% increase year-over-year.
- TG THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $17.40M, a 66.58% increase year-over-year.
- TG THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $68.21M, a 47.23% increase from fiscal 2024.
- TG THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $46.33M, a 13.49% increase from fiscal 2023.
- TG THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $40.82M, a 8.61% decline from fiscal 2022.
- TG THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $44.66M, a 27.11% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $13.09M 10-Q · filed 2026-08-05 | $27.65M derived: sum of 2 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $14.56M 10-Q · filed 2026-08-05 | ||||
| 2025-12-31 | $68.21M 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | $18.13M 10-Q · filed 2025-11-05 | $35.53M derived: sum of 2 quarters · filed 2026-08-05 | $51.50M derived: sum of 3 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $17.40M 10-Q · filed 2026-08-05 | $33.37M derived: sum of 2 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $15.97M 10-Q · filed 2026-08-05 | ||||
| 2024-12-31 | $46.33M 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | $12.66M 10-Q · filed 2025-11-05 | $23.10M derived: sum of 2 quarters · filed 2025-11-05 | $33.41M derived: sum of 3 quarters · filed 2025-11-05 | ||
| 2024-06-30 | $10.45M 10-Q · filed 2025-11-05 | $20.75M derived: sum of 2 quarters · filed 2025-11-05 | |||
| 2024-03-31 | $10.30M 10-Q · filed 2025-11-05 | ||||
| 2023-12-31 | $40.82M 10-K · filed 2026-02-27 | ||||
| 2023-09-30 | $9.97M 10-Q · filed 2024-11-07 | $23.55M derived: sum of 2 quarters · filed 2024-11-07 | $30.67M derived: sum of 3 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $13.58M 10-Q · filed 2024-11-07 | $20.70M derived: sum of 2 quarters · filed 2024-11-07 | |||
| 2023-03-31 | $7.12M 10-Q · filed 2024-11-07 | ||||
| 2022-12-31 | $44.66M 10-K · filed 2025-03-03 | $19.18M 10-K · filed 2023-03-01 | |||
| 2022-09-30 | $6.99M 10-Q · filed 2023-11-06 | $6.01M derived: sum of 2 quarters · filed 2023-11-06 | $8.13M derived: sum of 3 quarters · filed 2023-11-06 | ||
| 2022-06-30 | -$975.00K 10-Q · filed 2023-11-06 | $1.15M derived: sum of 2 quarters · filed 2023-11-06 | |||
| 2022-03-31 | $2.12M 10-Q · filed 2023-11-06 | ||||
| 2021-12-31 | $61.27M 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | $14.00M 10-Q · filed 2022-11-09 | $30.30M derived: sum of 2 quarters · filed 2022-11-09 | $46.92M derived: sum of 3 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $16.30M 10-Q · filed 2022-11-09 | $32.92M derived: sum of 2 quarters · filed 2022-11-09 | |||
| 2021-03-31 | $16.62M 10-Q · filed 2022-11-09 | ||||
| 2020-12-31 | $80.29M 10-K · filed 2023-03-01 | ||||
| 2020-09-30 | $28.33M 10-Q · filed 2021-11-08 | $35.70M derived: sum of 2 quarters · filed 2021-11-08 | $46.77M derived: sum of 3 quarters · filed 2021-11-08 | ||
| 2020-06-30 | $7.37M 10-Q · filed 2021-11-08 | $18.44M derived: sum of 2 quarters · filed 2021-11-08 | |||
| 2020-03-31 | $11.07M 10-Q · filed 2021-11-08 | ||||
| 2019-12-31 | $11.34M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $2.08M 10-Q · filed 2020-11-09 | $3.83M derived: sum of 2 quarters · filed 2020-11-09 | $5.71M derived: sum of 3 quarters · filed 2020-11-09 | $7.17M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-06-30 | $1.76M 10-Q · filed 2020-11-09 | $3.64M derived: sum of 2 quarters · filed 2020-11-09 | $5.10M derived: sum of 3 quarters · filed 2021-03-01 | $4.92M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-03-31 | $1.88M 10-Q · filed 2020-11-09 | $3.34M derived: sum of 2 quarters · filed 2021-03-01 | $3.17M derived: sum of 3 quarters · filed 2021-03-01 | $7.43M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2018-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.28M derived: sum of 2 quarters · filed 2021-03-01 | $5.55M derived: sum of 3 quarters · filed 2021-03-01 | $12.89M 10-K · filed 2021-03-01 | |
| 2018-09-30 | -$173.00K 10-Q · filed 2019-11-12 | $4.09M derived: sum of 2 quarters · filed 2019-11-12 | $11.43M 10-Q · filed 2018-11-09 | $15.00M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-06-30 | $4.26M 10-Q · filed 2019-11-12 | $11.60M 10-Q · filed 2018-08-09 | $15.17M derived: sum of 3 quarters · filed 2020-03-02 | $20.06M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-03-31 | $7.34M 10-Q · filed 2019-11-12 | $10.91M derived: sum of 2 quarters · filed 2020-03-02 | $15.80M derived: sum of 3 quarters · filed 2020-03-02 | $17.29M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2017-12-31 | $3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $8.46M derived: sum of 2 quarters · filed 2020-03-02 | $9.95M derived: sum of 3 quarters · filed 2020-03-02 | $15.95M 10-K · filed 2020-03-02 | $15.95M 10-K · filed 2018-03-15 |
| 2017-09-30 | $4.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $6.38M derived: sum of 2 quarters · filed 2017-11-09 | $12.38M 10-Q · filed 2017-11-09 | $13.70M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-06-30 | $1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $7.49M 10-Q · filed 2017-08-09 | $8.81M derived: sum of 3 quarters · filed 2019-03-01 | $11.65M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-03-31 | $6.00M 10-Q · filed 2017-05-10 | $7.32M derived: sum of 2 quarters · filed 2019-03-01 | $10.16M derived: sum of 3 quarters · filed 2019-03-01 | $11.81M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2016-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $4.16M derived: sum of 2 quarters · filed 2019-03-01 | $5.81M derived: sum of 3 quarters · filed 2019-03-01 | $7.51M 10-K · filed 2019-03-01 | $7.51M 10-K · filed 2017-03-16 |
| 2016-09-30 | $2.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $4.48M derived: sum of 2 quarters · filed 2016-11-09 | $6.18M 10-Q · filed 2016-11-09 | $9.04M derived: sum of 4 quarters · filed 2018-03-15 | |
| 2016-06-30 | $1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $3.35M 10-Q · filed 2016-08-09 | $6.20M derived: sum of 3 quarters · filed 2018-03-15 | $7.44M derived: sum of 4 quarters · filed 2018-03-15 | |
| 2016-03-31 | $1.70M 10-Q · filed 2016-05-10 | $4.56M derived: sum of 2 quarters · filed 2018-03-15 | $5.80M derived: sum of 3 quarters · filed 2018-03-15 | $12.04M derived: sum of 4 quarters · filed 2018-03-15 | |
| 2015-12-31 | $2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $4.10M derived: sum of 2 quarters · filed 2018-03-15 | $10.34M derived: sum of 3 quarters · filed 2018-03-15 | $15.70M 10-K · filed 2018-03-15 | |
| 2015-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $7.48M derived: sum of 2 quarters · filed 2015-11-09 | $12.84M 10-Q · filed 2015-11-09 | $17.88M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-06-30 | $6.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $11.60M 10-Q · filed 2015-08-10 | $16.64M derived: sum of 3 quarters · filed 2017-03-16 | $20.74M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-03-31 | $5.36M 10-Q · filed 2015-05-11 | $10.40M derived: sum of 2 quarters · filed 2017-03-16 | $14.49M derived: sum of 3 quarters · filed 2017-03-16 | $22.23M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2014-12-31 | $5.04M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $9.14M derived: sum of 2 quarters · filed 2017-03-16 | $16.87M derived: sum of 3 quarters · filed 2017-03-16 | $21.11M 10-K · filed 2017-03-16 | |
| 2014-09-30 | $4.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $11.84M derived: sum of 2 quarters · filed 2014-11-14 | $16.07M 10-Q · filed 2014-11-14 | $17.01M derived: sum of 4 quarters · filed 2016-03-15 | |
| 2014-06-30 | $7.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-24 | $11.97M 10-Q · filed 2014-07-24 | $12.92M derived: sum of 3 quarters · filed 2016-03-15 | $13.91M derived: sum of 4 quarters · filed 2016-03-15 | |
| 2014-03-31 | $4.23M 10-Q · filed 2014-05-14 | $5.18M derived: sum of 2 quarters · filed 2016-03-15 | $6.18M derived: sum of 3 quarters · filed 2016-03-15 | $7.55M derived: sum of 4 quarters · filed 2016-03-15 | |
| 2013-12-31 | $947.15K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $1.94M derived: sum of 2 quarters · filed 2016-03-15 | $3.32M derived: sum of 3 quarters · filed 2016-03-15 | $5.20M 10-K · filed 2016-03-15 | |
| 2013-09-30 | $996.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $2.37M derived: sum of 2 quarters · filed 2013-11-14 | $4.26M 10-Q · filed 2013-11-14 | $2.45M derived: sum of 4 quarters · filed 2014-03-07 | |
| 2013-06-30 | $1.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $3.26M 10-Q · filed 2013-08-09 | $1.46M derived: sum of 3 quarters · filed 2014-03-07 | $2.28M derived: sum of 4 quarters · filed 2014-03-07 | |
| 2013-03-31 | $1.89M 10-Q · filed 2013-05-14 | $83.91K derived: sum of 2 quarters · filed 2014-03-07 | $902.00K derived: sum of 3 quarters · filed 2014-03-07 | ||
| 2012-12-31 | -$1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | -$983.48K derived: sum of 2 quarters · filed 2014-03-07 | $188.51K 10-K · filed 2014-03-07 | ||
| 2012-09-30 | $818.09K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-14 | $1.99M 10-Q · filed 2012-11-14 | |||
| 2012-06-30 | $1.17M 10-Q/A · filed 2012-09-07 | ||||
| 2011-12-31 | $86.49K 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |